Plasmacytoid dendritic cells are increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse by Longhini, Ana Leda F et al.
SHORT REPORT Open Access
Plasmacytoid dendritic cells are increased
in cerebrospinal fluid of untreated patients
during multiple sclerosis relapse
Ana Leda F Longhini
1†, Felipe von Glehn
1,2†, Carlos Otávio Brandão
1, Rosemeire FO de Paula
1, Fernando Pradella
1,
Adriel S Moraes
1, Alessandro S Farias
1, Elaine C Oliveira
1,3, Juan G Quispe-Cabanillas
1, Cassiana Horta Abreu
1,2,
Alfredo Damasceno
2, Benito P Damasceno
2, Konstantin E Balashov
4, Leonilda MB Santos
1*
Abstract
The plasmacytoid dendritic cells (pDCs) express a high level of Toll-like receptor 9 (TLR-9), which recognizes viral
DNA. Activated via TLR-9, pDCs also secrete large amounts of type I interferon which are involved either in
stimulation or down regulation of immune response in multiple sclerosis (MS). In the present study, we
determinate pDCs levels by flow cytometry in Cerebrospinal Fluid (CSF) and Peripheral Blood from MS patients in
relapsing and in remitting phases of the disease, comparing with other non-inflammatory diseases (OND). We
provide evidence that MS patients in relapse without any treatment have a significantly (p < 0.01) higher
percentage of pDCs in CSF than do patients in remission or those with OND. No change in the percentage of
pDCs was observed in the peripheral blood of any of these patients. The increase of pDCs in central nervous
system during relapse may be explained either by a virus infection or a down regulatory process.
Introduction
The pathogenesis of multiple sclerosis (MS) is mainly
driven by central nervous system-invading encephali-
togenic CD4 T lymphocytes of both the Th1 and
Th17 types. These effector cells can be down-
regulated by regulatory T lymphocytes [1]. One subset
of dendritic cells, the plasmacytoid dendritic cells
(pDCs), has been given particular emphasis due to its
importance in stimulating or down regulating effectors
T cells in MS [2].
These pDCs are present in the cerebrospinal fluid
(CSF), leptomeninges and demyelinating lesions of
patients with MS [3]. These cells express a high level of
Toll-like receptor 9 (TLR-9), which recognizes viral
DNA. Activated via TLR-9, pDCs secrete large amounts
of type I interferon [4]. The use of type I interferon as
an immunomodulator in the treatment of MS patients
has proved beneficial for patients with the relapsing/
remitting form of MS (RRMS), and the production of
this cytokine by the pDCs may suggest an important
immunomodulatory function of these cells.
In the present study, the concentration of pDCs in the
CSF and peripheral blood of MS patients during
relapsing and remitting phases of the disease was deter-
mined and compared to what is present in other non-
inflammatory neurological diseases (OND).
Patients and Methods
Peripheral venous blood (5 ml) and CSF (5-10 ml) sam-
ples were collected from patients with RRMS, as defined
by the revised McDonald criteria [5]. The MS patients
were divided into two groups: relapsing (six patients)
and in remission (eleven patients). Moreover, samples
were collected from 8 patients with other non-
inflammatory neurological diseases (OND). Relapse was
defined as recent onset (within 1-7 days) of clinical neu-
rological symptoms, but without any clinical or labora-
torial signs of infection at the time of lumbar puncture.
All patients included agreed to participate in the study,
which was approved by the University of Campinas
Committee for Ethical Research, and they signed a term
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are presented in Table 1.
Patients using corticosteroids or other immunosup-
pressive and immunomodulatory drugs at the time of
investigation were excluded from the study. The group
with OND consisted of eight patients with no clinical
evidence of any inflammatory process in the central ner-
vous system (CNS). Two patients had had an ischemic
stroke, two patients had pseudotumor cerebri, one had
psychiatric disorders, one had epilepsy, one had normal
pressure hydrocephalus and one patient had post
trauma headache.
Flow Cytometry Analysis
The proportion of pDCs (in %) in relation to other
mononuclear cells was determined by staining the CSF
and peripheral blood mononuclear cells (PBMC) with
anti-human BDCA2-mAb conjugated with APC (Milte-
nyi Biotec, Germany). Data were acquired for gating
mononuclear cells using a BD FACSCanto cytometer
(BD Biosciences, USA) and analyzed using BD FACS-
Diva software (BD Biosciences, USA). The p value was
determined using unpaired T-test.
Results and Discussion
The number of pDCs is significantly elevated in the CSF
of patients in the relapse phase of untreated MS com-
pared to patients in remission (Figure 1). Since there are
no differences in the number of these cells neither in
the PBMC nor in total number of cells in the CSF of
the same patients, pDCs must selectively increase in the
CNS during the relapse phase of disease. As far as we
know, this is the first observation of such an increase in
the percentage of pDCs in the CSF of MS patients in a
specific phase of the disease. A previous study reported
an elevated concentration of dendritic cells, mainly
pDCs, in patients with infections and other inflamma-
tory neurological diseases, including MS, but no men-
tion was made of variations during different phases of
the disease [6].
The ambivalent function of pDCs has been observed
in experimental autoimmune encephalomyelitis (EAE),
a model for studying MS. A recent report shows that
they promote priming of autoimmune Th17 in EAE,
whereas depletion of pDC prior to induction of the
disease decreases its severity [7]. Another recent study
has demonstrated that clinical signs of EAE are exacer-
bated considerably if the pDCs are depleted during the
peak period of the disease [2]. Thus, pDC depletion
significantly enhances the activation of CNS cells and
the production of cytokines such as IL-17 and IFN-g,
but not peripheral CD4 T cells [2]. Recent study devel-
oped in the EAE model, demonstrated that the tolero-
genic property of pDCs is associated with MHC class
II molecule in the presenting of neuroantigen to CD4
T cells. This specific-antigen stimulation induces regu-
latory T cells, which results in the reduction of the dis-
ease severity [8]. Moreover, pDCs also produce
indolamine 2, 3 dioxigenase (IDO), which is an enzyme
activated by both type I and type II Interferon, and is
involved in tryptophan catabolism. Its immunosuppres-
sive effect is linked to the reduction of local trypto-
phan concentration and to the activation of regulatory
T cells [9,10].
Also of relevance is the impact of treatment with
immunomodulators and the length of its use on the
presence of pDCs in CSF. There is no significant differ-
ence in the percentage of pDCs in the CSF when we
analyzed the group of MS patients treated and not trea-
ted with interferon beta IFNb (data not shown), sug-
gesting that the increase of pDCs is restricted to
patients in relapse.
Although the exact function of pDCs in the CNS
needs to be elucidated in future studies, the presence of
pDCs during the phase of relapse may be explained
either by a virus infection or by the regulation of inflam-
matory process. As the immune response evolves, the
increase in the production of pro-inflammatory cyto-
k i n e ss u c ha sI F N ss t i m u l a t e st h es e c r e t i o no fI D Ob y
pDCs, which in turn will activate regulatory T lympho-
cytes. This immunomodulatory response will probably
contribute to the reduction of inflammation in the CNS,
thus preparing this microenvironment for the remission
phase of MS.
Table 1 Demographic and baseline clinical characteristics of patients and controls
Patients # Age (years*) Gender F/M Time from first relapse (Years*) CSF cells/μl * Oligoclonal Bands
RRMS - Relapse 6 34 (30-47) 4/2 5 (1-8) 6 (0-17) 6+/0-
RRMS- remission 11 34 (26-61) 9/2 3 (1-8) 3 (1-23) 8+/3-
OND** 8 46 (30-64) 7/1 - 2 (0-5)
*Median (range)
**Other Neurological Diseases
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Figure 1 Concentration of pDCs in relation to other mononuclear cells in CSF and peripheral blood. (A) BDCA2 positive gated CSF cells,
dot plot representative of MS patients in relapse and in remission. (B) Percentage of pDCs in CSF, with data points representing individuals of
MS patients in relapse (6) and in remission (11) and in other neurological diseases (8). (C) Concentration of pDCs in peripheral blood, with data
points representing individuals. Data are shown as median and the statistically significant differences are indicated by *(p < 0.01).
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